ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 0924

Distinct Cell-Bound Complement Activation Products Associate with Disease Activity and Immune Transcriptional Signatures in SLE

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 1426

Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib

(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

9:00AM-11:00AM: Abstract Number: 1323

Distinct Treatment Responses in Patients with Rheumatoid Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post Hoc Analysis of FINCH 1

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 1417

Do Long-term Patient-reported Outcomes Improve Similarly in Psoriatic Arthritis and Axial Spondyloarthritis Patients Treated with Secukinumab? Results from the EuroSpA Collaboration

(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

9:00AM-11:00AM: Abstract Number: 1421

Domains Impacting Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors Receiving Guselkumab (COSMOS)

(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

9:00AM-11:00AM: Abstract Number: 1104

Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial

(1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 0931

Down-Regulation of Human NADH-Ubiquinone Oxidoreductase Chain 6 by N6-Methyladenosine Methylation Is Associated with Lupus CD4+ T Cell Activation

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 1037

Dual Energy Computed Tomography (DECT) Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Intensive Urate-Lowering Therapy

(1033–1051) Imaging of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1490

Early Experience with SGLT2i in Systemic Lupus Erythematosus

(1488–1512) SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1424

Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients

(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

9:00AM-11:00AM: Abstract Number: 1413

Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligoarticular Psoriatic Arthritis: 16-Week Results from FOREMOST

(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

9:00AM-11:00AM: Abstract Number: 1321

Effect of Subcutaneous Local Anaesthesia Prior to Intra-Articular Injection: An Open Label, Paired-group, Randomized Controlled Trial

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 1337

Effect of Tofacitinib Therapy on Angiotensin Converting Enzyme Activity in Rheumatoid Arthritis

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 1361

Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers

(1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1335

Effectiveness of Longstanding Exercise Therapy versus Usual Care in People with Rheumatoid Arthritis and Severe Functional Limitations: A Randomized Controlled Trial (L-EXTRA)

(1308–1344) RA – Treatments Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].